-
公开(公告)号：US5866114A
公开(公告)日：1999-02-02
申请号：US351292
申请日：1995-05-25
申请人： Jayvardhan Pandit , Jarmila Jancarik , Sung-Hou Kim , Kirston Koths , Robert Halenbeck , Anna Lisa Fear , Eric Taylor , Ralph Yamamoto , Andrew Bohm
发明人： Jayvardhan Pandit , Jarmila Jancarik , Sung-Hou Kim , Kirston Koths , Robert Halenbeck , Anna Lisa Fear , Eric Taylor , Ralph Yamamoto , Andrew Bohm
IPC分类号： C12N15/02 , A61K38/00 , C07K14/53 , C07K14/535 , C07K14/715 , C12N1/21 , C12N15/09 , C12N15/12 , C12N15/27 , C12P21/02 , C12R1/19 , G01N33/566 , A61K38/19
CPC分类号： C07K14/53 , C07K14/7153
摘要： The present invention is directed to methods for crystallizing macrophage colony stimulating factor (M-CSF) and to a crystalline M-CSF produced thereby. The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF. The invention is also directed to methods for screening M-CSF agonists and antagonists. In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.
摘要翻译： PCT No.PCT / US93 / 05548 Sec。 371日期：1995年5月25日 102（e）日期1995年5月25日PCT提交1993年6月9日PCT公布。 公开号WO93 / 25687 日期1993年12月23日本发明涉及结晶巨噬细胞集落刺激因子（M-CSF）和由此产生的结晶M-CSF的方法。 本发明还涉及使用从M-CSF的结晶学结构得到的信息来设计和产生M-CSF激动剂和拮抗剂的方法。 本发明还涉及筛选M-CSF激动剂和拮抗剂的方法。 此外，本发明涉及分离的，纯化的，可溶的和功能性的M-CSF受体。
-
公开(公告)号：US6025146A
公开(公告)日：2000-02-15
申请号：US462069
申请日：1995-06-05
申请人： Jayvardhan Pandit , Jarmila Jancarik , Sung-Hou Kim , Kirston Koths , Robert Halenbeck , Anna Lisa Fear , Eric Taylor , Ralph Yamamoto , Andrew Bohm
发明人： Jayvardhan Pandit , Jarmila Jancarik , Sung-Hou Kim , Kirston Koths , Robert Halenbeck , Anna Lisa Fear , Eric Taylor , Ralph Yamamoto , Andrew Bohm
CPC分类号： G01N33/6863 , G01N2333/53 , G01N2333/535 , G01N2500/00
摘要： The present invention is directed to methods for crystallizing macrophage colony stimulating factor. The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF. The invention is also directed to methods for screening M-CSF agonists and antagonists. In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.
摘要翻译： 本发明涉及结晶巨噬细胞集落刺激因子的方法。 本发明还涉及使用从M-CSF的结晶学结构得到的信息来设计和产生M-CSF激动剂和拮抗剂的方法。 本发明还涉及筛选M-CSF激动剂和拮抗剂的方法。 此外，本发明涉及分离的，纯化的，可溶的和功能性的M-CSF受体。
-
公开(公告)号：US06322779B1
公开(公告)日：2001-11-27
申请号：US08478712
申请日：1995-06-07
IPC分类号： A61K4500
CPC分类号： C07K14/53 , A61K38/00 , C07K1/1133 , Y10S930/14 , Y10S930/145
摘要： The present invention is directed to an isolated and purified, recombinant, unglycosylated and dimeric CSF-1, the dimeric CSF-1 being biologically active and essentially endotoxin and pyrogen-free, the dimeric CSF-1 consisting essentially of two monomeric human CSF-1 subunits. The present invention is further directed to pharmaceutical compositions comprising the same.
摘要翻译： 本发明涉及分离和纯化的重组，未糖基化和二聚体CSF-1，二聚体CSF-1是生物活性的并且基本上是内毒素和无热原的，基本上由两个单体人CSF-1组成的二聚体CSF-1 亚单位。 本发明进一步涉及包含其的药物组合物。
-
4.发明授权Native type II GAP, methods for purifying various GAPs and uses of GAPs to diagnose cancer 失效本地II型GAP，纯化各种GAP的方法和GAP用于诊断癌症的用途
公开(公告)号：US5830684A
公开(公告)日：1998-11-03
申请号：US624299
申请日：1990-12-07
申请人： Robert Halenbeck , Kirston Koths , Francis P. McCormick , Bonnee Rubinfeld , Edward C. O'Rourke , Robin Clark , Gail L. Wong , George Martin
发明人： Robert Halenbeck , Kirston Koths , Francis P. McCormick , Bonnee Rubinfeld , Edward C. O'Rourke , Robin Clark , Gail L. Wong , George Martin
IPC分类号： C07K14/00 , A61K38/00 , C07K1/16 , C07K14/47 , C07K16/30 , C12N15/12 , C12P21/02 , G01N33/50 , G01N33/53 , G01N33/573 , G01N33/574
CPC分类号： C07K14/4703 , C07K14/4706 , C07K16/30 , G01N33/5011 , G01N33/573 , G01N33/57496 , A61K38/00 , G01N2333/4707
摘要： Native Type II GAP (GTPase activating protein), its uses in cancer diagnosis, and methods for obtaining and purifying native and recombinant Types I and II GAPs are described.
摘要翻译： 描述了天然II型GAP（GTP酶激活蛋白），其在癌症诊断中的用途以及获得和纯化天然和重组I型和II型GAP的方法。
-
公开(公告)号：US5861150A
公开(公告)日：1999-01-19
申请号：US472520
申请日：1995-06-07
CPC分类号： C07K14/53 , C07K1/1133 , A61K38/00 , Y10S930/14 , Y10S930/145
摘要： The present invention is directed to a biologically active CSF-1 dimer comprising a first CSF-1 monomer and a second CSF-1 monomer, wherein at least one of the monomers is truncated at the C-terminus after residue position 223. The dimers also include point mutations in one or both of the CSF-1 monomer. The invention also includes pharmaceutical compositions that comprise the CSF-1 dimer in a pharmaceutical excipient.
摘要翻译： 本发明涉及包含第一CSF-1单体和第二CSF-1单体的生物活性CSF-1二聚体，其中至少一种单体在残基位置223之后的C末端截短。二聚体也 包括一个或两个CSF-1单体中的点突变。 本发明还包括在药物赋形剂中包含CSF-1二聚体的药物组合物。
-
公开(公告)号：US5651963A
公开(公告)日：1997-07-29
申请号：US334456
申请日：1994-11-04
CPC分类号： C07K14/53 , C07K1/1133 , A61K38/00 , Y10S930/14 , Y10S930/145
摘要： The present invention relates to the production of CSF-1 heterodimers and pharmaceutical formulations of the heterodimers. The heterodimers can be formed using CSF-1 monomers that have variations in sequence, N or C-terminal processing. For example, CSF/C.gradient.150 can be dimerized with LCSF/C.gradient. 190 to form a heterodimer. Dimerization may occur by separately preparing homodimers and mixing them together under the appropriate conditions. Thereafter, homodimers may be separated from the heterodimers by various chromatographic techniques. Once the heterodimers are isolated, pharmaceutical preparations can be prepared.
摘要翻译： 本发明涉及产生异源二聚体的CSF-1异二聚体和药物制剂。 异二聚体可以使用具有序列变化，N或C末端加工的CSF-1单体形成。 例如，CSF / C NABLA 150可以用LCSF / C NABLA 190二聚化以形成异二聚体。 二聚可以通过单独制备同型二聚体并在合适的条件下将它们混合在一起而发生。 此后，可以通过各种色谱技术将同二聚体与异二聚体分离。 一旦异源二聚体被分离，就可以制备药物制剂。
-
公开(公告)号：US06184354B2
公开(公告)日：2001-02-06
申请号：US08462794
申请日：1995-06-05
申请人： Kirston Koths , Eric Taylor
发明人： Kirston Koths , Eric Taylor
IPC分类号： C07K1453
CPC分类号： C07K14/53 , C07K14/7153
摘要： The present invention is directed to methods for crystallizing macrophage colony stimulating factor. The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF. The invention is also directed to methods for screening M-CSF agonists and antagonists. In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.
摘要翻译： 本发明涉及结晶巨噬细胞集落刺激因子的方法。 本发明还涉及使用从M-CSF的结晶学结构得到的信息来设计和产生M-CSF激动剂和拮抗剂的方法。 本发明还涉及筛选M-CSF激动剂和拮抗剂的方法。 此外，本发明涉及分离的，纯化的，可溶的和功能性的M-CSF受体。
-
公开(公告)号：US5419899A
公开(公告)日：1995-05-30
申请号：US879753
申请日：1992-05-06
申请人： Kirston Koths , James Thomson , Michael Kunitani , Kenneth Wilson , Wolf Hanisch
发明人： Kirston Koths , James Thomson , Michael Kunitani , Kenneth Wilson , Wolf Hanisch
IPC分类号： C12N15/09 , A61K38/00 , A61P35/00 , C07K1/113 , C07K1/14 , C07K1/20 , C07K14/00 , C07K14/52 , C07K14/54 , C07K14/55 , C12N15/26 , C12P21/00 , C12P21/02 , C12R1/19 , A61K38/20
CPC分类号： C07K1/1133 , C07K14/55 , A61K38/00
摘要： A process for recovering microbially produced IL-2 in a highly pure form from the cellular material of the microorganisms that produced it comprising: disrupting the cell membranes of the microorganisms; extracting the disruptate with a chaotropic agent, such as urea, that selectively extracts microbial proteins from the cellular material; solubilizing the IL-2 in the solid phase of the extraction, mixture with an aqueous solution of a solubilizing agent, such as SDS, containing a reducing agent; and separating the IL-2 from the resulting solution by an optional extraction with 2-butanol or 2-methyl-2-butanol followed by gel filtration chromatography, oxidizing the IL-2 and purifying the oxidized IL-2 by RP-HPLC.
摘要翻译： 从产生它的微生物的细胞材料中回收高纯度形式的微生物产生的IL-2的方法，包括：破坏微生物的细胞膜; 用诸如尿素的离液剂提取破坏物，其从细胞材料中选择性提取微生物蛋白质; 将IL-2溶解在提取的固相中，与含有还原剂的增溶剂如SDS的水溶液混合; 并通过任选用2-丁醇或2-甲基-2-丁醇萃取，然后用凝胶过滤层析，将IL-2与所得溶液分离，氧化IL-2并通过RP-HPLC纯化氧化的IL-2。
-
9.发明授权Compositions containing reduced, microbially produced interleukin-2 (IL-2) 失效含有还原的，微生物产生的白细胞介素-2（IL-2）
公开(公告)号：US5614185A
公开(公告)日：1997-03-25
申请号：US428895
申请日：1995-04-25
申请人： Kirston Koths , James Thomson , Michael Kunitani , Kenneth Wilson , Wolf Hanisch
发明人： Kirston Koths , James Thomson , Michael Kunitani , Kenneth Wilson , Wolf Hanisch
IPC分类号： C12N15/09 , A61K38/00 , A61P35/00 , C07K1/113 , C07K1/14 , C07K1/20 , C07K14/00 , C07K14/52 , C07K14/54 , C07K14/55 , C12N15/26 , C12P21/00 , C12P21/02 , C12R1/19 , A61K38/20
CPC分类号： C07K1/1133 , C07K14/55 , A61K38/00
摘要： A process for recovering microbially produced IL-2 in a highly pure form from the cellular material of the microorganisms that produced it comprising: disrupting the-cell membranes of the microorganisms; extracting the disruptate with a chaotropic agent, such as urea, that selectively extracts microbial proteins from the cellular material; solubilizing the IL-2 in the solid phase of the extraction mixture with an aqueous solution of a solubilizing agent, such as SDS, containing a reducing agent; and separating the IL-2 from the resulting solution by an optional extraction with 2-butanol or 2-methyl-2-butanol followed by gel filtration chromatography, oxidizing the IL-2 and purifying the oxidized IL-2 by RP-HPLC.
摘要翻译： 从产生它的微生物的细胞材料中回收高纯度形式的微生物产生的IL-2的方法，包括：破坏微生物的细胞膜; 用诸如尿素的离液剂提取破坏物，其从细胞材料中选择性提取微生物蛋白质; 用含有还原剂的增溶剂如SDS的水溶液将IL-2溶解在萃取混合物的固相中; 并通过任选用2-丁醇或2-甲基-2-丁醇萃取，然后用凝胶过滤层析，将IL-2与所得溶液分离，氧化IL-2并通过RP-HPLC纯化氧化的IL-2。
-
10.发明申请Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis 审中-公开预防和治疗与癌症转移相关的癌症转移和骨丢失的方法公开(公告)号：US20110091451A1
公开(公告)日：2011-04-21
申请号：US10914598
申请日：2004-08-09
IPC分类号： A61K39/395 , A61P35/00 , A61P19/08
CPC分类号： A61K39/39558 , C07K16/243
摘要： M-CSF antagonists are used to prepare compositions, including pharmaceutical compositions, for preventing or treating cancer metastasis and/or bone loss associated with cancer metastasis in a mammal.
摘要翻译： M-CSF拮抗剂用于制备用于预防或治疗与哺乳动物癌症转移相关的癌症转移和/或骨丢失的组合物，包括药物组合物。
-
-
-
-
-
-
-
-
-
搜索结果
14 条记录 (耗时 0.037 秒)
